Overview
Virtual Event
Under the theme of “New Challenges, New Solutions: to overcome with people all over the world together”, this year’s JAM will provide opportunities for stakeholders from industry, government, academia, and patient bodies to look back at what we have accomplished and learned during the COVID-19 pandemic and engage in deeper dialogues as we move to the next stage.
This year’s conference will be held entirely online through a fully integrated platform offering live and on-demand content, 1-2-1 chat and Community meetups, live Q&A during sessions and much more! Sessions will also be available to view for one month following the live event. Breaking walls and boundaries, the virtual platform will enable you to join the event from wherever you may be and to connect with fellow professionals from across the world.
We look forward to your participation!
Super Early Bird savings available thru August 24th! Click Register below to save your seat.
-------------------
Call for Abstracts: Session Topics and Poster Presentations
DIA Japan is calling for Session Topic and Poster Presentation abstracts for the 18th DIA Japan Annual Meeting 2021.The program for this year’s event will be largely based on submitted abstracts.
Session Topics: Abstracts should be for a 60-minute session with multiple speakers and panel discussion, or
a 60-minute discussion-based session.
Poster Presentations: Abstracts should be for a poster presentation delivered by an individual presenter.
Posters should focus on the results of a study conducted by an individual or a group.
Submission Deadlines
Session Topics: Friday, April 16th, 2021
Poster Presentations: Sunday May 16th, 2021
Please see our Guidelines for full details.
Program Committee
-
E. Stewart Geary, MD • Senior VP, Global Safety Officer, Director, Corporate Medical Affairs HQ
Eisai Co., Ltd., Japan -
Rie Matsui, RPh • Senior Director, Regional Labeling Head for APAC
Pfizer R&D, Japan -
Katsuhiko Ichimaru • Director of MID-NET Operation and Management
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Kazuhiko Ishida, MSc, RPh •
Astellas Pharma Inc., Japan -
Tomoyuki Kakizume, PhD • Clinical Development Japan, Integrated Biostatistics Japan Department
Novartis Pharma K.K., Japan -
Miyuki Kaneko • Japan Regulatory Portfolio Lead, Regulatory Affairs
Pfizer R&D Japan, Japan -
Yukihiro Matsuda, MSc • Project Manager, Project Leadership
PRA Health Sciences K.K., Japan -
Yukiko Nishimura, PhD, MSc • President
NPO ASrid, Japan -
Mika Ogasawara • Quality Lead, Biometrics and Data Management
Pfizer R&D Japan, Japan -
Takashi Sato, MSc, PMP • Manager, Project Management Group, R&D Planning Department
Kyowa Kirin Co., Ltd., Japan -
Katsuhiko Sawada, MPharm • Director, Research and Development Dept.
Otsuka Medical Devices Co.Ltd., Japan -
Kazuyuki Suzuki, MSc • Oncology Trial Management Group, Trial Management Department, Japan Development
Novartis Pharma K.K., Japan -
Keiko Tsumori • Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Nariaki Uemura • Senior Associate, Depelopment
Astellas Pharma Inc., Japan -
Tadashi Urashima, PhD • Performance and Digital Analytics Lead, Medical & Development Excellence Japan
GlaxoSmithKline K.K., Japan -
Koichiro Yuji, MD, PhD, FACP • Project Associate Professor, The Institute of Medical Science
The University of Tokyo, Japan -
Keiichi Inaizumi, MSc • Japan Clinical Project Manager, Clinical Operations and Compliance 1
Pfizer R&D Japan, Japan -
Junichi Nishino, MSc, RPh • Director, Medical Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Hironobu Saito, PhD • Corporate Officer /Head of Medical Affairs Div.
Daiichi Sankyo Co., Ltd., Japan -
Junko Sato, PhD • Director, Office of International Programs
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Atsushi Tsukamoto, PhD, MSc •
Daiichi Sankyo Company, Limited, Japan